Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab

Bone Marrow Transplantation volume 36, pages 821–824 (2005)Cite this article

Summary:

Alemtuzumab is a humanized monoclonal antibody directed against human CD52 with a strong lympholytic effect. We have performed unmanipulated hematopoietic stem cell transplantation (HSCT) from 2- or 3-locus-mismatched family donors in 14 patients using in vivo alemtuzumab. All achieved complete donor cell engraftment and grade III–IV acute graft-versus-host disease was observed in only one patient. However, eight of the 14 patients developed grade II–IV cardiac complications according to Bearman's criteria. Next, we retrospectively analyzed the records of 142 adult patients who underwent allogeneic HSCT from 1995 to 2004 to evaluate whether the use of alemtuzumab was an independent risk factor for cardiac complications. Among several factors that increased the incidence of grade II–IV cardiac complications with at least borderline significance, a multivariate analysis identified the cumulative dose of anthracyclines (P=0.0016) and the use of alemtuzumab (P=0.0001) as independent significant risk factors. All of the cardiac complications in the alemtuzumab group were successfully treated with diuretics and/or catecholamines. Patient selection and close monitoring of cardiac function may be important in HLA-mismatched HSCT using in vivo alemtuzumab.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Hale G . The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001; 3: 137–143.

    Article  CAS  Google Scholar 

  2. Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071–1078.

    Article  CAS  Google Scholar 

  3. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419–2425.

    CAS  Google Scholar 

  4. Faulkner RD, Craddock C, Byrne JL et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004; 103: 428–434.

    Article  CAS  Google Scholar 

  5. Ho AY, Pagliuca A, Kenyon M et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616–1623.

    Article  CAS  Google Scholar 

  6. Peggs KS, Mackinnon S, Williams CD et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003; 9: 257–265.

    Article  Google Scholar 

  7. Kanda Y, Oshima K, Asano-Mori Y et al. In vivo alemtuzumab enables haploidentical HLA-mismatched hematopoietic stem cell transplantation without ex vivo graft manipulation. Transplantation 2005; 79: 1351–1357.

    Article  CAS  Google Scholar 

  8. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  Google Scholar 

  9. Sakata-Yanagimoto M, Kanda Y, Nakagawa M et al. Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33: 1043–1047.

    Article  CAS  Google Scholar 

  10. Ferrajoli A, O'Brien SM, Cortes JE et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003; 98: 773–778.

    Article  CAS  Google Scholar 

  11. Kennedy GA, Seymour JF, Wolf M et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 2003; 71: 250–256.

    Article  CAS  Google Scholar 

  12. Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001; 98: 1721–1726.

    Article  CAS  Google Scholar 

  13. Pawson R, Dyer MJ, Barge R et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997; 15: 2667–2672.

    Article  CAS  Google Scholar 

  14. Lenihan DJ, Alencar AJ, Yang D et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004; 104: 655–658.

    Article  CAS  Google Scholar 

  15. Mann DL . Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91: 988–998.

    Article  CAS  Google Scholar 

  16. Blum A, Miller H . Pathophysiological role of cytokines in congestive heart failure. Annu Rev Med 2001; 52: 15–27.

    Article  CAS  Google Scholar 

  17. Spitzer TR . Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893–898.

    Article  CAS  Google Scholar 

  18. Niwa N, Watanabe E, Hamaguchi M et al. Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Ann Hematol 2001; 80: 460–465.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported in part by grants from the Ministry of Health, Labor and Welfare of Japan.

Author information

Authors and Affiliations

  1. Department of Cell Therapy & Transplantation Medicine, University of Tokyo Hospital, Tokyo, Japan

    K Oshima, M Sakata-Yanagimoto, Y Asano-Mori, K Izutsu, T Watanabe, E Shoda, S Ogawa, T Motokura, S Chiba, M Kurokawa, H Hirai & Y Kanda

Authors
  1. K Oshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Sakata-Yanagimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Asano-Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Izutsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Shoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Motokura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Chiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Kurokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H Hirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Y Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Kanda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oshima, K., Sakata-Yanagimoto, M., Asano-Mori, Y. et al. Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab. Bone Marrow Transplant 36, 821–824 (2005). https://doi.org/10.1038/sj.bmt.1705145

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705145

Keywords

This article is cited by

Search

Advanced search

Quick links